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GP = glycoproteins; MI = myocardial infarction; rt-PA = recombinant tissue-type plasminogen activator; TIMI = thrombolysis in MI.
ADMIRAL = Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term follow-up; BRAVO = Block-
ade of the GP IIb/IIIa Receptor to Avoid Vascular Occlusion; CAPTURE = c7E3 Antiplatelet Therapy in Unstable Refractory Angina; EPIC = Evalua-
tion of c7E3 for Prevention of Ischemic Complications; EPILOG = Evaluation in PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa
Blockade; EPISTENT = Evaluation of Platelet Inhibition in Stenting; ESPRIT = Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin
Therapy; EXCITE = Evaluation of Xemilofiban in Controlling Thrombotic Events; GUSTO IV-ACS = Global Use of Strategies To Open Occluded
Arteries — IV — Acute Coronary Syndrome; IMPACT II = Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis — II; OPUS-TIMI 16 =
Orofiban in Patients with Unstable Coronary Syndromes Thrombolysis in MI; PARAGON = Platelet IIb/IIIa Antagonism for the Reduction of Acute
Coronary Syndrome events in the Global Organization Network; PRISM = Platelet Receptor Inhibition in Ischemic Syndrome Management; PRISM-
PLUS = Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs; PURSUIT = Platelet IIb/IIIa in Unsta-
ble Angina: Receptor Suppression Using Integrilin Therapy; RAPPORT = ReoPro and Primary PTCA Organization and Randomized Trial;
RESTORE = Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis; SYMPHONY = Sibrafiban Versus Aspirin to Yield Maximum
Protection From Ischemic Heart Events Post Acute Coronary Syndromes; TACTICS-TIMI 18 = Treat Angina with Aggrastat and Determine Cost of
Therapy with an Invasive or Conservative Strategy — Thrombolysis in Myocardial Infarction 18; TARGET = Do Tirofiban and Reopro Give Similar
Efficacy Trial.
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Platelets play a pivotal role in acute coronary syndromes
[1,2]. Plaque rupture exposes highly thrombogenic com-
ponents that induce platelet activation and initiate coagu-
lation cascade. Platelet activation involves a
conformational change in the membrane glycoproteins
(GP) that are receptors for adhesive proteins [3]. The
recent development of a new class of drugs that allow
direct inhibition of platelet GP IIb/IIIa receptors, the ‘final
common pathway’ of platelet activation, has raised the
possibility that these potent agents may reduce throm-
botic complications after percutaneous coronary interven-
tions or in acute coronary syndromes [4]. In the following
review, we summarize the trials conducted to evaluate the
use of GP IIb/IIIa inhibitors in these clinical settings, and
discuss issues of efficacy and safety.
Intravenous GP IIb/IIIa antagonists
Four intravenous GP IIb/IIIa antagonists have been investi-
gated: abciximab (c7E3 Fab), eptifibatide (Integrilin),
tirofiban (Aggrastat), and lamifiban (Ro 44-9883) (Table 1).
Percutaneous coronary interventions
The role of periprocedural intravenous GP IIb/IIIa inhibition
in percutaneous coronary revascularization was estab-
lished in nine placebo-controlled randomized trials and
one comparative trial enrolling, in total, over 24,000
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Abstract
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in
acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been
the subject of a number of large controlled trials using both the intravenous and the oral forms. In this
review, we present a systematic overview of these trials.
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patients [5–19]. All trials were blinded throughout the
follow-up period. Inclusion criteria varied (Table 2).
The EPIC trial
The Evaluation of c7E3 for Prevention of Ischemic Compli-
cations (EPIC) trial included only patients at higher risk
than normal for ischemic complications [5]. The adminis-
tration of an intravenous bolus and 12-hour infusion of
abciximab resulted in a 35% reduction of relative risk of
the primary endpoint and reduced the risk of procedure-
related myocardial infarction (MI). This benefit was more
pronounced in patients with unstable angina and those
undergoing angioplasty for MI. The major limitation of the
EPIC trial, however, was the existence of a substantially
increased risk of bleeding subsequently attributed to the
high heparin doses.
The EPILOG trial
The Evaluation in PTCA to Improve Long-term Outcome
with Abciximab GP IIb/IIIa Blockade (EPILOG) trial
extended the application of abciximab to all patients under-
going coronary angioplasty, using the same abciximab
Table 1
Intravenous glycoprotein IIb/IIIa antagonists
Abciximab Eptifibatide Tirofiban Lamifiban
Structure Antibody Fab fragment Cyclic heptapeptide Non-peptide Non-peptide
Plasma half-life 10–30 min ~2.5 h ~2 h ~2 h
Excretion Unknown ~50% renal 39–69% renal 90% renal
Table 2
Randomized placebo-controlled interventional trials with intravenous glycoprotein (GP) IIb/IIIa inhibitors
Trial (number of patients) Agent tested Entry criteria Primary endpoints
EPIC (2099) Abciximab High-risk patients undergoing PCI 30-day composite endpoint: death, MI, CABG, 
or repeat PCI
EPILOG (2792) Abciximab Patients with low and high risk undergoing  30-day composite endpoint: death, MI, CABG, or 
PCI repeat PCI
EPISTENT (2399) Abciximab Patients undergoing elective or urgent  30-day composite endpoint: death, MI, CABG, or 
coronary intervention suitable for  repeat PCI
balloon angioplasty or stenting
IMPACT II (4010) Eptifibatide Patients undergoing elective, urgent or  30-day composite endpoint: death, MI, unplanned 
emergency coronary interventions CABG, or repeat PCI
RESTORE (2139) Tirofiban Patients undergoing balloon angioplasty  30-day composite endpoint: death, MI, CABG, or 
or directional atherectomy within 72 hours  repeat angioplasty and stent
of ACS
CAPTURE (1265) Abciximab Refractory unstable angina Death, MI, or urgent intervention for recurrent 
ischemia, within 30 days
RAPPORT (483) Abciximab Within 12 hours of the onset of acute MI,  All-cause mortality, non-fatal MI, fatal MI, urgent 
referred for angioplasty target vessel revascularization at 6 months
ESPRIT (2064) Eptifibatide Undergoing non-urgent PCI with a variety  Combined endpoint: death, MI, or urgent repeat 
of stents revascularization, and need for bail-out GP IIb/IIIa 
receptor blockade at 48 hours
ADMIRAL (300) Abciximab Patients undergoing stenting for symptoms  Composite of death, reinfarction or urgent 
of acute MI within 12 hours of enrollment  revascularization at 30 days
and ST-elevation MI
TACTICS-TIMI 18 Tirofiban  Patients with unstable angina and non-ST- Composite of death, non-fatal myocardial 
(2220) (invasive versus  elevation MI infarction and rehospitalization for an acute 
conservative strategy) coronary syndrome
TARGET (4812) Tirofiban versus  Non-acute MI, PCI with ‘intent to stent’ Death, MI, or urgent revascularization, at 30 days
abciximab
ACS, Acute coronary syndromes; CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary revascularization.c
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regimen as the EPIC trial, but with a lower heparin dose
[6]. There was a 56% reduction in the relative risk of the
30-day endpoint, with a substantial reduction in the risk of
bleeding — from 14% in EPIC to just 2% in EPILOG.
The CAPTURE trial
The c7E3 Antiplatelet Therapy in Unstable Refractory
Angina (CAPTURE) trial enrolled patients with unstable
angina requiring coronary angioplasty [7]. Patients were
treated with an abciximab infusion for 18–24 hours before
angioplasty but for only 1 hour afterwards. The trial
reported a 23% reduction in the relative risk of primary
endpoints after 30 days.
The EPISTENT trial
The Evaluation of Platelet Inhibition in Stenting (EPISTENT)
trial assessed the efficacy of abciximab with coronary
stenting in patients undergoing elective or urgent coronary
intervention [8–10]. Patients were randomized to receive
either stenting with placebo, stenting with abciximab, or
balloon angioplasty with abciximab. The primary endpoint
at 30 days confirmed the efficacy of abciximab with a 51%
decrease in the relative risk of death, MI or urgent revascu-
larization. This benefit was maintained throughout the 6-
month follow-up period. Furthermore, the rate of repeat
intervention on target vessels following stent implantation
in diabetics was significantly reduced (by 51%) with treat-
ment with abciximab. Moreover, after 1 year, the combina-
tion of stenting and abciximab resulted in a significant
reduction (60%) in mortality compared with either therapy
administered alone.
The RAPPORT
The ReoPro and Primary PTCA Organization and Ran-
domized Trial (RAPPORT) focused on angioplasty as a
primary reperfusion strategy for MI with acute ST elevation
[11]. A total of 483 patients were assigned, within
12 hours of the onset of acute MI, to receive either an
abciximab bolus followed by infusion of abciximab for
12 hours or placebo. Abciximab significantly reduced the
incidence of death, reinfarction, or urgent target vessel
revascularization at all time points assessed (at 7 days,
9.9% versus 3.3%, P = 0.003; at 30 days, 11.2% versus
5.8%, P = 0.03; and at 6 months, 17.8% versus 11.6%,
P = 0.05). A higher incidence of major bleeding was noted
in the abciximab group (16.6% versus 9.5%, P = 0.02),
similar to the EPIC trial in which a higher dose of heparin
was also used.
The IMPACT II and ESPRIT trials
Eptifibatide was evaluated in patients undergoing coro-
nary intervention in the Integrilin to Minimize Platelet
Aggregation and Coronary Thrombosis — II (IMPACT II)
[12] trial and the Enhanced Suppression of the Platelet
IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial
[13,14].
Patients undergoing balloon angioplasty or directional
atherectomy in the IMPACT II trial were randomly assigned
to receive either a bolus and 24-h low-dose infusion
(0.5 g/kg/min) of eptifibatide, or a bolus and high-dose
infusion (0.75 g/kg/min) of eptifibatide, or placebo.
Although there was no significant reduction in the primary
composite endpoint after 30 days with eptifibatide, there
was a 10.5% reduction in ischemic events when data from
the two eptifibatide groups were combined.
The ESPRIT trial, in contrast, enrolled patients undergoing
routine stent implantation [13]. The patients were random-
ized to receive either eptifibatide in two 180 µg/kg
boluses 10 min apart with a continuous infusion of
2.0 µg/g/min for 18–24 hours, or placebo. The results
showed a significant reduction in the primary endpoints
from 10.5 to 6.6% (P = 0.0017). There was a 38% reduc-
tion in the relative risk of death or MI at 30 days (6.3%
versus 10.2%, P = 0.002), which was maintained through-
out the 6-month follow-up period (7.5% versus 11.5%,
P = 0.002, 95% confidence interval = 0.47–0.84) [14].
The higher dose of eptifibatide used in the ESPRIT trial
resulted in more platelet inhibition (90–95%) than in the
IMPACT II trial (50–60%) and may have contributed to a
better outcome.
The GOLD study
The GOLD study was a prospective multicenter study to
determine the optimal level of platelet inhibition with
GPIIb/IIIa inhibitors in patients undergoing coronary inter-
vention [15]. This study of GP IIb/IIIa inhibition in conjunc-
tion with percutaneous coronary intervention found that
patients who achieved greater than 70% inhibition had
much lower rates of major cardiac events than patients
with lower levels of inhibition (12% versus 32%, P = 0.02).
The RESTORE trial
Tirofiban was evaluated in patients with unstable angina
undergoing coronary intervention in the Randomized Effi-
cacy Study of Tirofiban for Outcomes and Restenosis
(RESTORE) trial [16]. A trend towards improvement in
outcome at 30 days was observed in the tirofiban-treated
patients when compared with placebo (10.3% versus
12.2%, P = 0.16). Furthermore, the bleeding rates were
low and not significantly different from placebo.
The ADMIRAL trial
The Abciximab before Direct Angioplasty and Stenting in
Myocardial Infarction Regarding Acute and Long-term
follow-up (ADMIRAL) trial randomized patients suffering
acute MI with ST elevation to either abciximab
(0.25 mg/kg bolus, 0.125 µg/kg/min [10 µg/kg/min
maximum] for 12 hours) plus stenting or placebo plus
stenting [17]. The composite endpoint of death, reinfarc-
tion or urgent revascularization at 30 days was signifi-
cantly lower in the abciximab group (6.0% versus 14.6%,
Available online http://cvm.controlled-trials.com/content/2/4/171P = 0.01) and remained significant throughout 6 months
of follow-up (7.4% versus 15.9%, P = 0.02). The better
clinical outcomes in the abciximab group were related to
the greater frequency of thrombolysis in MI (TIMI) grade 3
when compared with placebo (before the procedure,
16.8% versus 5.4%, P = 0.01; immediately after the pro-
cedure, 95.1% versus 86.7%, P = 0.04; and at 6 months
after the procedure, 94.3% versus 82.8%, P = 0.04). One
major bleeding event occurred in the abciximab group and
none occurred in the placebo group.
The TACTICS-TIMI 18 trial
The Treat Angina with Aggrastat and Determine Cost of
Therapy with an Invasive or Conservative Strategy — Throm-
bolysis in Myocardial Infarction 18 (TACTICS-TIMI 18) trial
studied patients with unstable angina and MI without ST
elevation [18]. Patients were treated with heparin and
tirofiban in a loading dose of 0.4 µg/kg, followed by
0.1 µg/kg/min for 48 hours or until revascularization;
tirofiban was administered for at least 12 hours after percu-
taneous revascularization. Patients were randomized to
receive either early invasive strategy with routine catheteri-
zation (within 4–48 hours) or conservative treatment with
catheterization reserved for recurrent pain or provocable
ischemia. When compared with conservative therapy, the
combination of tirofiban and early invasive strategy resulted
in significant reduction in the primary endpoints of death,
myocardial infarction or rehospitalization at 6 months
(15.9% versus 19.4%, P = 0.025). The rate of death or non-
fatal MI at 6 months was similarly reduced (7.3% versus
9.5%, P < 0.05). The benefit of the early invasive strategy
was greatest in high-risk and intermediate-risk patients with
elevated troponin T levels, whereas the outcome was similar
with the use of either strategy in patients at low risk and in
those without elevated troponin T levels.
TARGET
More recently, the Do Tirofiban and Reopro Give Similar
Efficacy Trial (TARGET) randomized patients undergoing
stenting for coronary artery disease, with or without an
acute coronary syndrome, to receive either abciximab or
tirofiban [19]. The combined primary endpoint of death,
MI, or urgent revascularization occurred in 7.6% of the
tirofiban group and 6.0% of the abciximab group
(P = 0.037). Abciximab was found to be superior particu-
larly in patients with acute coronary syndrome.
The difference in efficacy may, in part, be due to the phar-
macodynamics of receptor binding. Abciximab dissociates
slowly in contrast to the rapid reversibility of tirofiban. Fur-
thermore, the non-specific blockade by abciximab of both
the GP IIb/IIIa receptor and the αvβ3 receptor may theoret-
ically provide an advantage over tirofiban. Ex vivo studies
have suggested that dual receptor blockade more com-
pletely suppresses platelet-mediated thrombin generation
than does inhibition of either receptor alone [20].
Summary
In conclusion, as an adjunct to percutaneous coronary
interventions, GP IIb/IIIa inhibition results in a significant
reduction in early ischemic events that is sustained
throughout the 1-year follow-up period. Furthermore,
this benefit is independent of the interventional devices
used and of lesion complexities, and has been reported
across all the aforementioned interventional trials. Hem-
orrhagic risk was reduced when the heparin dose was
limited and the vascular sheath was removed early.
Rates of intracranial hemorrhage were not increased by
GP IIb/IIIa blockade. It unclear whether the superiority
of abciximab over tirofiban is related to the differences
in the mechanisms of antagonism of GP IIb/IIIa, the spe-
cific effects of abciximab in blocking interactions
between platelets and endothelial cells and leukocytes,
differences in doses, differences in patients, or statisti-
cal variation [21].
Acute coronary syndromes
The role of intravenous GP IIb/IIIa antagonists in the treat-
ment of unstable ischemic syndromes, independent of the
use of coronary revascularization, was tested in more than
31,000 patients in six placebo-controlled trials (Table 3)
[22–26].
The PRISM trial
The Platelet Receptor Inhibition in Ischemic Syndrome
Management (PRISM) trial randomized patients with
unstable angina or non-Q-wave MI to receive either stan-
dard heparin or a 48-hour infusion of tirofiban [22]. At
48 hours, tirofiban was superior to heparin in reducing the
composite endpoint of death, MI and refractory ischemia
(3.8% versus 5.6%, P = 0.01), with a 36% reduction in
relative risk.
The PRISM-PLUS trial
Patients in the Platelet Receptor Inhibition in Ischemic
Syndrome Management in Patients Limited by Unstable
Signs (PRISM-PLUS) trial were randomized to receive
either tirofiban alone, tirofiban with heparin, or heparin
alone [23]. The tirofiban-only arm was subsequently dis-
continued because of a higher mortality rate than heparin
alone. The combination of tirofiban and heparin was,
however, superior to heparin in reducing the combined
endpoint of death, MI and recurrent ischemia after 7 days
(12.9% versus 17.9%, P = 0.004). This significant differ-
ence persisted throughout 6 months of follow-up (18.5%
versus 22.3%, P = 0.03).
The PURSUIT trial
In the Platelet IIb/IIIa in Unstable Angina: Receptor Sup-
pression Using Integrilin Therapy (PURSUIT) trial, an epti-
fibatide infusion for 72 hours reduced the combined
incidence of death or MI by 10% after 30 days (14.2%
versus 15.7%, P = 0.04) [24].
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The Platelet IIb/IIIa Antagonism for the Reduction of Acute
Coronary Syndrome events in the Global Organization
Network (PARAGON A [25] and PARAGON B [26])
trials, in contrast to PRISM, PRISM-PLUS and PURSUIT,
failed to demonstrate an advantage of lamifiban over
placebo. This failure did not include results in patients with
elevated troponin-T levels (30-day composite endpoint,
11% versus 19.4%, P = 0.01).
The GUSTO IV-ACS trial
Similarly disappointing results have recently been demon-
strated in the Global Use of Strategies To Open
Occluded Arteries — IV — Acute Coronary Syndrome
(GUSTO IV-ACS) trial [27]. A total of 7800 patients with
non-ST-elevation acute coronary syndromes, for whom
percutaneous coronary interventions were not planned,
were randomized to receive either 24 hours of abciximab,
48 hours of abciximab, or placebo. Abciximab use in this
trial was not associated with a reduced risk of death or MI
after 30 days (8% for placebo, 8.2% for 24-hour abcix-
imab and 9.2% for 48-hour abciximab; not significant).
Summary
In conclusion, high-risk patients (patients with ST depres-
sion or elevated troponin levels) should receive GP IIb/IIIa
inhibitors (either tirofiban or eptifibatide) in addition to the
usual antithrombotic regimen.
Adjuncts to reperfusion therapy
Several completed and ongoing studies are evaluating the
role of GP IIb/IIIa inhibitors as an adjunct to thrombolytic
therapy.
The TAMI 8 trial
The Thrombolysis and Angioplasty in MI (TAMI 8) trial was
a preliminary dose-ranging trial, testing abciximab com-
bined with thrombolytic therapy [28]. Sixty patients with
acute MI receiving recombinant tissue-type plasminogen
activator (rt-PA) also received a bolus injection of abcix-
imab. The infarct-related artery was patent in 56% of
control patients and 92% of the GP IIb/IIIa inhibitor
patients. The incidence of major bleeding was increased
in the control group (abciximab, 25% versus control,
50%).
The PARADIGM trial
The Platelet Aggregation Receptor Antagonist Dose
Investigation and Reperfusion Gain in MI (PARADIGM)
trial studied patients with acute MI who received treatment
with either alteplase or streptokinase [29]. The patients
were randomly assigned treatment with either adjunctive
lamifiban or placebo. Despite the higher patency of the
infarct-related artery in the lamifiban group when com-
pared with placebo (75% versus 62.5%), the clinical out-
comes in the lamifiban and placebo groups were not
significantly different (death, 2.1% versus 2.6%; reinfarc-
Available online http://cvm.controlled-trials.com/content/2/4/171
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Table 3
Randomized acute ischemic syndrome trials for intravenous glycoprotein IIb/IIIa blockade
Trial (number of patients) Agent tested Entry criteria Primary endpoints
PURSUIT (10,948) Eptifibatide CP at rest or minimal exertion within  Death, and non-fatal MI, at 30 days
24 hours and either ischemic ECG 
changes* or CK-MB elevations
PRISM-PLUS (1915) Tirofiban CP at rest or minimal exertion within  Death, MI, or refractory ischemia, at 7 days
12 hours and either ischemic ECG 
changes* or CK-MB elevations
PRISM (3232) Tirofiban CP at rest or minimal exertion within  Death, MI or refractory ischemia, at 48 hours
24 hours and ischemic ECG changes* 
or CK-MB elevations or history of CAD or 
positive stress test
PARAGON A (2282) Lamifiban CP at rest within 12 hours and ischemic  Death, and non-fatal MI, at 30 days
ECG changes*
PARAGON B (5225) Lamifiban Patients within 12 hours of symptoms of  The composite incidence of death, MI, or SRI, at 
acute myocardial ischemia and ECG changes* 30 days
GUSTO IV-ACS (7800) Abciximab ACS within last 24 hours; > 5 min anginal  All-cause mortality, composite endpoint of death, 
symptoms at rest, and either + troponin I/T,  or MI, at 30 days
or ST depression ≥ 0.5 mm
ACS, Acute coronary syndromes; CAD, coronary artery disease; CK-MB, creatine kinase MB isoenzyme; CP, Chest pain; ECG, electrocardiogram;
MI, myocardial infarction; SRI, severe refractory ischemia. * ST depression, T inversion or transient ST elevation.tion, 8.9% versus 6.0%; refractor ischemia, 6.4% versus
8.5%; and revascularization, 11.4% versus 12.0%). Fur-
thermore, there was more bleeding associated with lami-
fiban (transfusions, 16% versus 10.3%; major bleeding,
3.0% versus 1.7%).
The IMPACT-AMI trial
The Integrilin to Minimize Platelet Aggregation and Prevent
Coronary Thrombosis AMI (IMPACT-AMI) trial was a ran-
domized, placebo-controlled, dose-ranging trial in which
132 patients who received accelerated alteplase (rt-PA)
were randomized to eptifibatide (Integrilin) or placebo
[30]. Patients treated with the highest eptifibatide dose
achieved 90-min TIMI 3 flow in 66% of patients, compared
with 39% of patients receiving placebo. Composite clini-
cal end-points were similar in both groups (43% versus
42%). The incidence of excessive bleeding was not
increased in the active treatment group compared with the
placebo group (4% versus 5%).
The TIMI 14 trial
In the Thrombolysis in MI (TIMI 14) trial, 888 patients who
suffered a MI with ST elevation were randomized to
receive either 100 mg accelerated-dose alteplase
(control), abciximab alone, or abciximab in combination
with either reduced doses of alteplase (20, 35, or 65 mg)
or streptokinase (500,000 U–1.5 MU) [31]. Excessive
bleeding was noted with the highest dose of streptokinase
plus abciximab, and this arm was discontinued after five
patients were enrolled. The most promising regimen was
the combination of abciximab and a 50 mg dose of
alteplase, which resulted in 77% TIMI grade 3 flow at 90
min compared with 62% for alteplase alone (P = 0.02).
This improvement in reperfusion with alteplase occurred
without an increase in the risk of major bleeding.
The SPEED trial
The Strategies for Patency Enhancement in the Emer-
gency Department (SPEED) trial was a dose escalation
trial testing the combination of abciximab and reteplase in
patients with acute MI [32,33]. All patients received a full-
dose of abciximab (0.25 mg/kg bolus, 0.125 µg/kg/min
[10 µg/kg/min maximum] for 12 hours) and were randomly
assigned in a 4:1 ratio to receive either reteplase (5, 7.5,
10, or 5 + 5 U) with abciximab, or abciximab alone. TIMI 3
flow in the various groups at 60 min was 19% (abciximab
alone), 52% (5 U reteplase plus abciximab), 48% (7.5 U
reteplase plus abciximab), 51% (10 U reteplase plus
abciximab) and 62% (5 + 5 U reteplase plus abciximab).
The GUSTO V trial
In the Global Use of Strategies To Open Occluded Arter-
ies — V (GUSTO V) trial, a total of 16,588 patients who suf-
fered an acute MI with ST elevation were randomized to
receive two bolus doses of reteplase (10 U) or two half-
boluses of reteplase (5 U) with a full dose of abciximab
(0.25 mg/kg bolus, 0.125 µg/kg/min [10 µg/kg/min
maximum] for 12 hours) [34]. The medication was adminis-
tered on an open label basis. The combination of half-dose
reteplase and abciximab has failed to show a significant
reduction in mortality at 30 days compared with full-dose
reteplase alone (5.6% versus 6.9%, P = 0.43). The trial
did, however, show that the combination was ‘non-inferior’
to the fibrinolytic alone. There were, however, fewer deaths
or reinfarctions with the combination (7.4% versus 8.8%,
P = 0.001) and less need for urgent revascularization, but
more non-cranial bleeds (severe bleeding, 1.1% versus
0.5%, P < 0.0001; moderate bleeding, 3.5% versus 1.8%,
P < 0.0001; transfusion, 5.7% versus 4.0%, P < 0.0001).
Summary
In conclusion, the combination of intravenous GP IIb/IIIa
antagonists and fibrinolytic therapy results in more rapid
reperfusion than conventional therapy. The incidence of
30-day mortality was not reduced, however, and its use
was associated with more non-cranial bleeds. There are
other ongoing trials; both angiographic (i.e. looking at
effects on TIMI flow) with TNKase and each of the three
GP IIb/IIIa inhibitors (such as the Integrilin and
Tenecteplase for Acute Myocardial Infarction [INTEGRITI]
trial), and larger mortality trials (such as Assessment of
the Safety and Efficacy of a New Thrombolytic — III
[ASSENT III]) with TNKase and abciximab. These
ongoing trials are exploring further the potential role of
GP IIb/IIIa inhibitors combined with reduced doses of
thrombolytic therapy and may further clarify its role as an
adjunct to reperfusion therapy.
Oral platelet GP IIb/IIIa antagonists
Prodrugs with RGD specificity (Arg-Gly-Asp sequence)
now include oral GP IIb/IIIa receptor blockers, such as
xemilofiban, orofiban, sibrafiban and lotrafiban, which
have longer half-lives and are excreted renally. Five trials
evaluated the use of these agents in patients with acute
coronary syndrome or undergoing percutaneous coro-
nary intervention. Four of these trials enrolled patients
presenting with acute coronary syndromes and one trial
enrolled patients undergoing percutaneous coronary
interventions (Table 4).
The EXCITE trial
The Evaluation of Xemilofiban in Controlling Thrombotic
Events (EXCITE) trial compared xemilofiban (10–20 mg,
administered 3 times a day for 2 weeks) with placebo in
7232 patients undergoing percutaneous coronary inter-
ventions [35]. The primary endpoint was death, recurrent
MI, and urgent revascularization at 30 and 182 days. The
incidence of death, MI, and urgent revascularization within
182 days was comparable among the three groups
(13.5% in placebo, 13.9% in those receiving 10 mg
xemilofiban, and 12.7% in those receiving 20 mg
xemilofiban).
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The Orofiban in Patients with Unstable Coronary Syn-
dromes Thrombolysis in MI (OPUS-TIMI 16) trial random-
ized 10,302 patients presenting with acute coronary
syndromes [36]. They received either 50 mg orofiban
twice daily for 6 months, 50 mg orofiban for 30 days fol-
lowed by 30 mg twice daily for 6 months, 50 mg orofiban
twice daily for 5 months, or placebo. The primary endpoint
was death, recurrent MI, recurrent ischemia requiring
rehospitalization or revascularization, and stroke, at
30 days and at 10 months. This trial was stopped prema-
turely because of a statistically significant increase in mor-
tality observed after 30 days with orofiban therapy (2.0%
versus 1.4%, P = 0.02).
The SYMPHONY trials
The Sibrafiban Versus Aspirin to Yield Maximum Protec-
tion From Ischemic Heart Events Post Acute Coronary
Syndromes (SYMPHONY [37] and SECONDSYMPHONY
[38]) trials studied sibrafiban, with doses adjusted to
weight and serum creatinine, in acute coronary syndrome
patients. The SYMPHONY trial randomized 9233 patients
to low-dose sibrafiban, high-dose sibrafiban, or aspirin
therapy for 90 days. The SECONDSYMPHONY trial com-
pared the same low-dose regimen of sibrafiban with
aspirin or high-dose sibrafiban without aspirin with aspirin
therapy alone for 90 days. The primary endpoint for both
studies was death, MI, and severe recurrent ischemia
requiring revascularization at 90 days. The SYMPHONY
trial demonstrated a lack of benefit with sibrafiban com-
pared with aspirin alone (9.8% aspirin, 10.1% low-dose
sibrafiban and 10.1% high-dose sibrafiban). This SECOND
SYMPHONY trial was terminated prematurely, after 6637
patients were enrolled, when the results of the SYM-
PHONY trial were known.
The BRAVO trial
The Blockade of the GP IIb/IIIa Receptor to Avoid Vascu-
lar Occlusion (BRAVO) trial studied the role of lotrafiban
in patients who had suffered a recent MI, unstable angina,
transient ischemic attack or a stroke, or patients who pre-
sented at any time after a diagnosis of peripheral vascular
disease [39]. The trial was stopped when it was found at
an interim analysis that lotrafiban had a higher mortality
than placebo (2.7% versus 2.0%, P = 0.022), more major
bleeding (4.2% versus 1.3%, P < 0.022) and a greater
incidence of serious thrombocytopenia (2.2% versus
0.5%) [26].
Summary
Overall, each trial reported an increased risk of mortality
during the follow-up period, with an overall 31% increase
in mortality. Furthermore, high-dose GP IIb/IIIa inhibition is
associated with an even greater fatality risk. No trial
demonstrated a statistically significant effect on MI. Con-
versely, the need for urgent revascularization was reduced
in each study except in the EXCITE trial. Moreover, a sta-
tistically significant increase in bleeding was observed in
each trial. In a meta-analysis of the first four published
trials, Chew et al demonstrated that there was a consis-
tent and statistically significant increase in mortality with
oral GP IIb/IIIa therapy (odds ratio = 1.37, 95% confi-
dence interval = 1.13–1.66, P = 0.001) [40].
Conclusion
Intravenous GP IIb/IIIa inhibition used as an adjunct to per-
cutaneous coronary interventions results in significant
reduction in early ischemic events that may be sustained
for 1 year. This benefit is independent of the interventional
devices used and independent of lesion complexities.
Abciximab seems to provide better results than eptifi-
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Table 4
Randomized placebo-controlled trials with oral glycoprotein IIb/IIIa inhibitors
Trial (number of patients)Agent tested Indications Entry criteria Primary endpoints
EXCITE (7232) Xemilofiban PCI Patients with angiographic evidence of  Death, MI, and recurrent revascularization, 
significant CAD requiring PCI at 30 and 182 days
OPUS-TIMI 16 Orofiban ACS Unstable coronary syndromes; Q-wave  Death, MI, and recurrent ischemia, 
(10,302) MI, non-Q-wave MI, and UA, in preceding  revascularization, or stroke, at 30 days and 
72 hours with either ECG changes,  6 months
enzyme elevation, or prior CAD
SYMPHONY (9233) Sibrafiban ACS ACS event after stabilization Death, MI, and severe recurrent ischemia, 
at 90 days
SECONDSYMPHONY  Sibrafiban ACS ACS event after stabilization Death, MI, and severe recurrent ischemia, 
(6671) at 90 days
BRAVO (9200) Lotrafiban ACS + CVA Recent MI, UA, TIA or stroke, or PVD Death, stroke, recurrent ischemia, or 
revascularization, at 6 months–2 years 
(stopped prematurely)
ACS, Acute coronary syndromes; CAD, coronary artery disease; CVA, cerebrovascular accident; ECG, electrocardiogram; MI, myocardial
infarction; PCI, percutaneous coronary interventions; PVD, peripheral vascular disease; TIA, transient ischemic attack; UA, unstable angina.batide. Preliminary data suggest that intravenous GP
IIb/IIIa inhibition may be a useful adjunct to conventional
thrombolytic therapy by accelerating the process of fibri-
nolysis. However, this awaits confirmatory evidence on the
efficacy and safety of this combination regimen from
ongoing megatrials.
In contrast to the beneficial effects of intravenous GP
IIb/IIIa inhibitors, oral GP IIb/IIIa inhibitors were associated
with a significant increase in mortality. Further investiga-
tion to elucidate the cause of this increased fatality risk is
warranted.
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